Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double blind, randomized placebo controlled study of the efficacy, safety and tolerability of quetiapine fumarate sustained release (Seroquel SRTM) in the treatment of major depression with comorbid fibromyalgia syndrome.

Next Previous
Trial Profile

A double blind, randomized placebo controlled study of the efficacy, safety and tolerability of quetiapine fumarate sustained release (Seroquel SRTM) in the treatment of major depression with comorbid fibromyalgia syndrome.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Feb 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Fibromyalgia; Major depressive disorder
  • Focus Therapeutic Use

Most Recent Events

  • 01 Feb 2014 Results published in the Arthritis and Rheumatology.
  • 09 Oct 2013 Primary endpoint 'Hamilton-Depression-Rating-Scale' has been met.
  • 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top